ly 353381 has been researched along with bexarotene in 1 studies
| Studies (ly 353381) | Trials (ly 353381) | Recent Studies (post-2010) (ly 353381) | Studies (bexarotene) | Trials (bexarotene) | Recent Studies (post-2010) (bexarotene) |
|---|---|---|---|---|---|
| 70 | 12 | 15 | 642 | 67 | 348 |
| Protein | Taxonomy | ly 353381 (IC50) | bexarotene (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 5.9 | |
| Retinoic acid receptor RXR-alpha | Homo sapiens (human) | 0.632 | |
| Cytochrome P450 26B1 | Homo sapiens (human) | 5.9 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hede, K | 1 |
1 other study(ies) available for ly 353381 and bexarotene
| Article | Year |
|---|---|
Rexinoids may be ready for prime time in prevention, but challenges remain.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Breast Neoplasms; Clinical Trials as Topic; Disease Models, Animal; Female; Humans; Nicotinic Acids; Piperidines; Retinoid X Receptors; Tetrahydronaphthalenes; Thiophenes | 2004 |